Ebos Group (Ebos Group) Risk Assessment

View and export this data going back to 2014. Start your Free Trial

What is Ebos Group Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Ebos Group is: No Data: Cannot be evaluated.

Competitive Comparison of Ebos Group's Risk Assessment

For the Medical Distribution subindustry, Ebos Group's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ebos Group's Risk Assessment Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Ebos Group's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Ebos Group's Risk Assessment falls into.

Ebos Group (OTCPK:EBOSF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Ebos Group Risk Assessment Related Terms

Thank you for viewing the detailed overview of Ebos Group's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Ebos Group (Ebos Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Ebos Group Ltd (OTCPK:EBOSF) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

EBO:New Zealand EJG:Germany EBO:Australia

Address

108 Wrights Road, P.O. Box 411, Christchurch, STL, NZL, 8024

Website

https://www.ebosgroup.com

Ebos is the largest pharmaceutical wholesaler and distributor across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 60% and 30% of revenue respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low single digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.

Ebos Group (Ebos Group) Headlines

From GuruFocus

Half Year 2024 EBOS Group Ltd Earnings Call Transcript

By GuruFocus Research • 02-28-2024